MYCN Amplification and International Neuroblastoma Risk
Grouping [INRG]
A total of 46 cases were evaluated after excluding 4 cases (due to
technical reasons); 48% (22/46) cases showed MYCN amplification
and 52% (24/46) showed no amplification.
INRG risk stratification of the cohort was performed by combining age,
stage, histologic category/grade, ploidy, and MYCN status. Majority were
in the high-risk group (n=36, 60%) followed by intermediate-risk group
(n=13, 22%) and low-risk group (n=11, 18%) respectively.